Development of biomimetic oligomers as anticoagulant antagonists

作为抗凝拮抗剂的仿生寡聚物的开发

• 批准号: 7867938
• 负责人: RICHARD W SCOTT
• 金额: $ 36.97万
• 依托单位: POLYMEDIX, INC,
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-21 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7867938
• 关键词: ADME Study; Acute; Adverse event; Affect; Animals; Anticoagulants; Anticoagulation; Antidotes; Back; Binding; Biological Assay; Biomimetics; Cardiac; Cell Line; Chemicals; Chemistry; Clinical; Clinical Research; Clinical Trials; Coagulants; Coagulation Process; Complement Activation; Complication; Coronary Artery Bypass; Dalteparin; Death Rate; Deep Vein Thrombosis; Derivation procedure; Development; Dose; Drug Kinetics; Drug or chemical Tissue Distribution; Electrophysiology (science); Endothelial Cells; Enoxaparin; Enzymes; Erythrocytes; Exhibits; Fibrin; Fibroblasts; Frequencies; Goals; Hemorrhage; Heparin Antagonists; High-Risk Pregnancy; Human; In Vitro; Investigational New Drug Application; Kilogram; Lead; Life; Light; Low-Molecular-Weight Heparin; Medical; Membrane Proteins; Methods; Modeling; Operative Surgical Procedures; Orthopedic Surgery procedures; Patients; Peptides; Pharmaceutical Chemistry; Pharmacodynamics; Pharmacology; Phase; Plasma; Principal Investigator; Process; Property; Protamines; Protein Binding; Proteins; Publishing; Pulmonary Embolism; Rattus; Regimen; Reporting; Research; Research Design; Resistance; S Phase; Safety; Series; Serum; Solutions; Structure; Testing; Therapeutic Index; Toxic effect; Unstable angina; acute coronary syndrome; animal efficacy; base; cancer therapy; cytotoxic; cytotoxicity; design; dosage; drug development; experience; fondaparinux; hemodynamics; heparin pentasaccharide; improved; in vitro activity; in vivo; novel; phase 2 study; physical property; preclinical efficacy; preclinical evaluation; programs; public health relevance; receptor; safety study; salicylamide; scaffold; scale up

DESCRIPTION (provided by applicant): LMWHs are being used with greater frequency to treat deep vein thrombosis, unstable angina, and acute pulmonary embolism, as well as thromboprophylaxis agents in a wide range of clinical situations including orthopedic surgery, high risk pregnancy, and cancer therapy. The most common complication of anticoagulation with LMWHs is hemorrhage. Many published clinical studies report 1% to 4% major (life-threatening) bleeding associated with LMWH therapy and there is a 5-fold increase in the overall death rate for acute coronary syndrome patients receiving anti- coagulant therapy that experience major bleeding. Although protamine is commonly used to neutralize UFH following coronary bypass surgery, it is unable to completely reverse the anticoagulant effects of LMWHs or fondaparinux. Therefore, there is a strong medical need for the development of a safe and effective antagonist for the LMWHs. The goal would be to develop an antidote that could rapidly reverse unwanted bleeding yet permit rapid resumption of anticoagulation therapy with a new dose of LMWH to restore thromboprophylaxis. We are developing series of non-peptidic oligomers with well-defined secondary or tertiary structures to serve as novel templates for the design of compounds targeting specific protein- protein and protein-membrane interactions. These oligomers have many advantages over peptides: relatively smaller size which increases stability and enhances tissue distribution, ease of synthesis, resistance to proteolytic degradation, and suitability for medicinal chemistry approaches to fine-tune their physical properties and optimize potency and safety. We have utilized this strategy to design small oligomers that strongly interact with UFH and LMWH and antagonize their anti-coagulation properties. We propose to evaluate the suitability of current lead compounds as antagonists to LMWH and fondaparinux in preclinical efficacy and safety studies designed to identify clinical candidates. In addition, we propose to continue medicinal chemistry efforts in the salicylamide series and a newer series of arylamides to identify back-up compounds to substitute into the discovery program if problems are encountered with the current lead compounds. PUBLIC HEALTH RELEVANCE: Low molecular weight heparins (LMWHs) and the pentasaccharide, fondaparinux, are widely used anti-coagulants employed in a number of clinical and surgical applications. Bleeding complications are common adverse events associated with anti-coagulant therapy. Protamine is an effective antagonist of UFH but presently there are no effective antagonists for the pentasaccharide or the low molecular weight heparins. We are developing safe and effective non-peptidic oligomers to neutralize the anti-coagulation properties of LMWH and fondaparinux.

描述（由申请方提供）：LMWH正以更高的频率用于治疗深静脉血栓形成、不稳定型心绞痛和急性肺栓塞，以及在广泛的临床情况下作为血栓预防剂，包括骨科手术、高危妊娠和癌症治疗。低分子量肝素抗凝最常见的并发症是出血。许多已发表的临床研究报告了1%至4%与LMWH治疗相关的大出血（危及生命），并且接受抗凝治疗的急性冠状动脉综合征患者发生大出血的总死亡率增加了5倍。虽然鱼精蛋白通常用于中和冠状动脉搭桥手术后的UFH，但它不能完全逆转低分子肝素或磺达肝癸钠的抗凝作用。因此，医学上迫切需要开发一种安全有效的LMWH拮抗剂。我们的目标是开发一种解毒剂，可以迅速逆转不必要的出血，但允许快速恢复抗凝治疗与新剂量的低分子肝素，以恢复血栓预防。我们正在开发一系列具有明确二级或三级结构的非肽寡聚物，以作为设计靶向特定蛋白质-蛋白质和蛋白质-膜相互作用的化合物的新型模板。这些寡聚体与肽相比具有许多优点：相对较小的尺寸，这增加了稳定性并增强了组织分布，易于合成，对蛋白水解降解具有抗性，以及适用于药物化学方法以微调其物理性质并优化效力和安全性。我们已经利用这种策略来设计与UFH和LMWH强烈相互作用并拮抗其抗凝特性的小寡聚物。我们建议在临床前有效性和安全性研究中评估当前先导化合物作为LMWH和磺达肝癸钠拮抗剂的适用性，这些研究旨在确定临床候选药物。此外，我们建议继续在水杨酰胺系列和较新的芳基酰胺系列中进行药物化学研究，以确定备用化合物，以便在当前先导化合物遇到问题时替代发现计划。公共卫生关系：低分子量肝素（LMWH）和五糖磺达肝癸钠是在许多临床和外科应用中广泛使用的抗凝剂。出血并发症是与抗凝治疗相关的常见不良事件。鱼精蛋白是UFH的有效拮抗剂，但目前还没有针对五糖或低分子量肝素的有效拮抗剂。我们正在开发安全有效的非肽低聚物，以中和LMWH和磺达肝癸钠的抗凝特性。